Dynamic modelling of protein and oxidative metabolisms simulates the pathogenesis of Parkinson's disease

IET Systems Biology

Volumn 6, Issue 3, 2012, Pages 65-72

  Cloutier, M ^a,b   Wellstead, P ^b  

^a GERAD   (Canada)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR PROCESS; COMPLEX CONDITION; COMPUTATIONAL STUDIES; FEEDBACK INTERACTION; GENETIC DEFECTS; HUMAN BRAIN; IN-SILICO; OXIDATIVE METABOLISM; PARKINSON'S DISEASE; REACTIVE OXYGEN SPECIES; RISK FACTORS; SYNUCLEIN;

MATHEMATICAL MODELS; ORDINARY DIFFERENTIAL EQUATIONS; OXYGEN;

NEURODEGENERATIVE DISEASES;

ALPHA SYNUCLEIN; OXYGEN; REACTIVE OXYGEN METABOLITE;

AGING; ARTICLE; BIOLOGICAL MODEL; BRAIN; COMPUTER SIMULATION; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; OXYGEN CONSUMPTION; PARKINSON DISEASE;

AGING; ALPHA-SYNUCLEIN; BRAIN; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; OXYGEN; OXYGEN CONSUMPTION; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES;

PARKINSONIA;

EID: 84863542914     PISSN: 17518849     EISSN: None     Source Type: Journal    
DOI: 10.1049/iet-syb.2011.0075     Document Type: Article

References (52)

1. Lotharius, J., and Brundin, P.: 'Pathogenesis of Parkinson's disease', Nat. Rev. Neurosci., 2002, 3, p. 933-94210.1038/nrn983
2. Litvan, I., Halliday, G., and Hallett, M.: et al. 'The etiopathogenesis of Parkinson's disease and suggestions for future research', J. Neuropathol. Exper. Neurol. 1., 2007, 66, (5), p. 251-25710.1097/nen.0b013e3180415e42
3. Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., and Del Tredici, K.: 'Stages in the development of Parkinson's disease-related pathology', Cell Tissue Res., 2004, 318, (1), p. 121-13410.1007/s00441-004-0956-9
4. Powers, W.J., Videen, T.O., and Markham, J.: et al. 'Cerebral mitochondrial metabolism in early Parkinson's disease', J. Cereb. Blood Flow Metab., 2008, 28, p. 1754-176010.1038/jcbfm.2008.63
5. Langston, J.W., and Palfreman, J.: 'The case of the frozen addicts', (Pantheon Press 1996)
6. Jenner, P.: 'Oxidative stress in Parkinson's disease', Ann. Neurol., 2003, 53, (3), p. S26-3610.1002/ana.10483
7. Gibb, W.R., and Lees, A.J.: 'The relevance of the Lewy body to the pathogenesis of idopathic Parkinson's disease', J. Neurol. Neurosurg. Psychiatry., 1988, 51, (6), p. 745-75210.1136/jnnp.51.6.745
8. Malkus, K.A., Tsika, E., and Ischiropoulos, H.: 'Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle', Mol. Neurodegeneration, 2009, 4, p. 2410.1186/1750-1326-4-24
9. Marambaud, P., Dreses-Werringloer, U., and Vingtdeux, V.: 'Calcium signaling in neurodegeneration', Mol. Neurodegeneration, 2009, 4, p. 2010.1186/1750-1326-4-20
10. Chan, C.S., Gertler, T.S., and Surmeier, D.J.: 'Calcium homeostasis, selective vulnerability and Parkinson's disease', Trends Neurosci., 2009, 32, (5), p. 249-25610.1016/j.tins.2009.01.006
11. Cookson, M.R.: 'α-Synuclein and neuronal cell death', Mol. Neurodegeneration, 2009, 4, p. 910.1186/1750-1326-4-9
12. Devi, L., Raghavendran, V., Prabhu, B.M., Avadhani, N.G., and Anandatheerthavarada, H.K.: 'Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain', J. Biol. Chem., 2008, 283, (14), p. 9089-910010.1074/jbc.M710012200
13. Martin, L.J., Pan, Y., and Price, A.C.: et al. 'Parkinson's disease alpha-synuclein transgenic mice develops neuronal mitochondrial degeneration and cell death', J. Neurosc., 2006, 26, p. 41-5010.1523/JNEUROSCI.4308-05.2006
14. Klivenyi, P., Siwek, D., and Gardian, G.: et al. 'Mice lacking alpha-synuclein are resistant to mitochondrial toxins', Neurobiol. Dis., 2006, 21, p. 541-54810.1016/j.nbd.2005.08.018
15. Maroteaux, L., Campaneli, J.T., and Scheller, R.H.: 'Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal', J. Neurosci., 1988, 8, p. 2804-2815
16. Mosharov, E.V., Larsen, K.E., and Kanter, E.: et al. 'Interplay between cytosolic dopamine, calcium and alpha-synuclein causes selective death of substantia nigra neurons', Neuron., 2009, 62, p. 218-22910.1016/j.neuron.2009.01.033
17. Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., and Lansbury, P.T.: 'Neurodegenerative disease: amyloid pores from pathogenic mutations', Nat. Rev. Neurosci., 2002, 418, p. 29110.1038/418291a
18. van Rooijen, B.D., Claessens, M.M.A.E., and Subramaniam, V.: 'Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core', Biochimica et Biophysica acta., 2009, 1788, p. 1271-127810.1016/j.bbamem.2009.03.010
19. Fai Poon, H., Frasier, M., and Shreve, N.: et al. 'Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice - a model of familial Parkinson's disease', Neurobiol. Dis., 2005, 18, p. 492-49810.1016/j.nbd.2004.12.009
20. Pellerin, L., and Magistretti, P.J.: 'Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization', Proc. Natl. Acad. Sci., 1994, 91, p. 10625-1062910.1073/pnas.91.22.10625
21. Cloutier, M., and Wellstead, P.: 'The control systems structures of energy metabolism', J. R. Soc. Interface, 2010, 7, (45), p. 651-66510.1098/rsif.2009.0371
22. Wellstead, P., and Cloutier, M.: 'An energy systems approach to Parkinson's disease', Wiley Interdiscip. Rev. Syst. Biol. Med., 2010, 3, (1), p. 1-610.1002/wsbm.107
23. Haefner, J.W.: 'Modelling biological systems: principles and applications', (Chapman and Hall 1996), p. 496
24. Tyson, J.J., Chen, K.C., and Novak, B.: 'Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signalling pathways in the cell', Curr. Opin. Cell Biol., 2003, 15, p. 221-23110.1016/S0955-0674(03)00017-6
25. Raichur, A., Vali, S., and Gorin, F.: 'Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson's disease', Neuroscience, 2006, 142, p. 859-87010.1016/j.neuroscience.2006.06.052
26. Bharathi, P., Nagabhushan, P., and Rao, K.S.J.: 'Mathematical approach to understand the kinetics of alpha-synuclein aggregation: relevance to Parkinson's disease', Comput. Biol. Med., 2008, 38, p. 1084-109310.1016/j.compbiomed.2008.08.008 0010-4825
27. Sneppen, K., Lizana, L., Jensen, M.H., Pigolotti, S., and Otzen, D.: 'Modelling proteasome dynamics in Parkinson's disease', Phys. Biol., 2009, 6, p. 03600510.1088/1478-3975/6/3/036005 1478-3967
28. Vali, S., Mythri, R.B., and Jagatha, B.: et al. 'Integrating gluthatione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model', Neuroscience, 2007, 149, p. 917-93010.1016/j.neuroscience.2007.08.028
29. Qi, Z., Miller, G.W., and Voit, E.O.: 'Computational systems analysis of dopamine metabolism', PLoS ONE., 2008, 3, p. e244410.1371/journal.pone.0002444
30. Qi, Z., Miller, G.W., and Voit, E.O.: 'Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals', Synapse, 2009, 63, p. 1133-114210.1002/syn.20686
31. Best, J.A., Nijhout, H.F., and Reed, M.C.: 'Homeostatic mechanisms in dopamine synthesis and release: a mathematical model', Theor. Biol. Med. Model., 2009, 6, p. 2110.1186/1742-4682-6-21
32. Cloutier, M., Bolger, F.B., Lowry, J.P., and Wellstead, P.: 'An integrative dynamic model of brain energy metabolism using in vivo neurochemical measurements', J. Comput. Neurosci., 2009, 27, (3), p. 391-41410.1007/s10827-009-0152-8 0929-5313
33. Schmidt, H., and Jirstrand, M.: 'Systems biology toolbox for matlab: a computational platform for research in systems biology', Bioinformatics, 2006, 22, (4), p. 514-51510.1093/bioinformatics/bti799
34. Meng, T.C., Somani, S., and Dhar, P.: 'Modeling and simulation of biological systems with stochasticity', In Silico Biol., 2004, 4, p. 0024
35. Bolger, F., Serra, P.A., O'Neill, R.D., Fillenz, M., and Lowry, J.P.: 'Real-time monitoring of brain extracellular lactate', Di Chiara, G., Carboni, E., Valentini, V., et al. (Eds.) Monitoring molecules in neuroscience, (University of Cagliari Press 2003)
36. Tanner, C.M., Kamel, F., and Ross, G.W.: et al. 'Rotenone, paraquat and Parkinson's disease', Environ. Health Perspect., 2011, 119, (6), p. 866-87210.1289/ehp.1002839
37. Lodish, H., Berk, A., and Kaiser, C.K.: 'Molecular cell biology', et al. (W.H. Freeman and Company 2000)
38. Turrens, J.F.: 'Mitochondrial formation of reactive oxygen species', J. Physiol., 2003, 552, (2), p. 335-34410.1113/jphysiol.2003.049478
39. Lei, B., Adachi, N., and Arai, T.: 'Measurement of the extracellular H2O2 in the brain by microdialysis', Brain Res. Protoc., 1998, 3, p. 33-3610.1016/S1385-299X(98)00018-X
40. Bennett, M.C., Bishop, J.F., and Leng, Y.: et al. 'Degradation of alpha-synuclein by proteasome', J. Biol. Chem., 1999, 274, p. 33855-3385810.1074/jbc.274.48.33855
41. Parihar, M.S., Parihar, A., Fujita, M., Hasimoto, M., and Ghafourifar, P.: 'Mitochondrial association of alpha-synuclein causes oxidative stress', Cell. Mol. Life Sci., 2008, 65, p. 1272-128410.1007/s00018-008-7589-1
42. Lee, V.M.Y., and Trojanowski, J.Q.: 'Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery', Neuron, 2006, 52, p. 33-3810.1016/j.neuron.2006.09.026
43. Bueler, H.: 'Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease', Exp. Neurol., 2009, 218, p. 235-24610.1016/j.expneurol.2009.03.006
44. Schapira, A.H., Cooper, J.M., and Dexter, D.: et al. 'Mitochondrial complex I deficiency in Parkinson's disease', J. Neurochem., 1990, 54, p. 823-82910.1111/j.1471-4159.1990.tb02325.x
45. Buttner, S., Bitto, A., and Ring, J.: et al. 'Functional mitochondria are required for alpha-synuclein toxicity in aging yeasts', J. Biol. Chem., 2008, 283, p. 7554-756010.1074/jbc.M708477200
46. Betarbet, R., Sherer, T.B., MacKenzie, G., Barcia-Osuna, M., Panov, A.V., and Greenamyre, J.T.: 'Chronic systemic pesticide exposure reproduces features of Parkinson's disease', Nat. Neurosci., 2000, 3, p. 1301-130610.1038/81834 1097-6256
47. Desagher, S., Glowinski, J., and Premont, J.: 'Astrocytes protect neurons from hydrogen peroxide toxicity', J. Neurosci., 1996, 16, p. 2553-2562
48. Song, D.D., Shults, C.W., Sisk, A., Rockenstein, E., and Masliah, E.: 'Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP', Exp. Neurol., 2004, 186, p. 158-17210.1016/S0014-4886(03)00342-X
49. Von Bohlen und Halbach, O., Schober, A., and Krieglstein, K.: 'Genes, proteins and neurotoxins involved in Parkinson's disease', Prog. Neurobiol., 2003, 73, p. 151-17710.1016/j.pneurobio.2004.05.002
50. Singleton, A.D., Farrer, M., and Johnson, J.: et al. 'Alpha-synuclein locus triplication causes Parkinson's disease', Science, 2003, 302, p. 841-84410.1126/science.1090278 0036-8075
51. Hughes, A.J., Daniel, S.E., Kilford, L., and Lees, A.J.: 'Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases', J. Neurol. Neurosurg. Psychiatry, 1992, 55, p. 181-18410.1136/jnnp.55.3.181
52. Lee, S.J.: 'Alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson's disease?', Antioxid. Redox Signal., 2003, 5, p. 337-34810.1089/152308603322110904